Maxim initiated coverage of Autonomix (AMIX) with a Buy rating and $5 price target
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMIX:
- Autonomix granted new European Patent for catheter-based technology
- Autonomix engages advisors to guide clinical, regulatory path in cancer pain
- Autonomix granted U.S. patent for catheter-based technology
- Autonomix advances toward U.S. clinical trials in 2025
- Autonomix files $200M mixed securities shelf